Les Groupes Coopérateurs en Oncologie à l`ASCO 2016
Transcription
Les Groupes Coopérateurs en Oncologie à l`ASCO 2016
Lettre d’information du réseau GCO - Spéciale ASCO 2016 Les Groupes Coopérateurs en Oncologie à l’ASCO 2016 Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO (American Society of Clinical Oncology), qui se tiendra du 3 au 7 juin à Chicago (Etats-Unis). L’ASCO est le principal rendez-vous de la cancérologie mondiale au cours duquel sont partagés les résultats d’études cliniques sur le traitement des cancers. Comme chaque année, les GCO présenteront leurs dernières études menées dans différentes pathologies cancéreuses essentiellement les cancers gynécologiques, digestifs, bronchiques, les cancers de la tête et du cou, les cancers du cerveau et du système nerveux central, les hémopathies malignes ainsi que les cancers pédiatriques. Nous vous invitons à découvrir dans cette lettre d’information les 10 communications orales et 25 posters qui portent sur des essais promus ou soutenus par l’un des neuf groupes membres des GCO. ----------------------------------------------------------------------------------------------------------------CANCERS DE LA TETE ET DU COU GORTEC : Groupe Oncologie Radiothérapie Tête et Cou Abstract 6000 (communication orale) Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN) : Results of the GORTEC 2007-02 phase III randomized trial. View abstract Abstract 6003 (communication orale) Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN) : Results of the GORTEC 2007-01 phase III randomized trial. View abstract 1 Lettre d’information des GCO - n°1 – Mai 2016 GCO/IFCT 10 rue de la Grange-Batelière - 75009 Paris Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/ CANCERS DIGESTIFS (COLORECTAUX ET NON COLORECTAUX) FFCD : Fédération Francophone de Cancérologie Digestive Abstract TPS4154 (poster) GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential Benefit of Adjuvant chemotherapy for smaLL bowel Adenocarcinoma (IRCI 002). View abstract Abstract 3531 (poster) Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer. View abstract Abstract 3534 (poster) Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC) : ancillary study of PRODIGE 9 trial. View abstract Abstract TPS4148 (poster) REMINET: A european, multicentre, phase II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with nonresectable duodeno-pancreatic neuroendocrine tumours. View abstract Abstract 3513 (poster) FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial. View abstract Abstract 3532 (poster) Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials. View abstract Abstract 3533 (poster) Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trials. View abstract GERCOR : Groupe Coopérateur Multidisciplinaire en Oncologie Abstract 3553 (poster) Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial. View abstract Abstract 4120 (poster) Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM). View abstract 2 Lettre d’information des GCO - n°1 – Mai 2016 GCO/IFCT 10 rue de la Grange-Batelière - 75009 Paris Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/ -------------------------------------------------------------------------------------------------------------------------------------CANCERS DU POUMON IFCT : Intergroupe Francophone en Cancérologie Thoracique Abstract 9005 (communication orale) Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE. View abstract Abstract 9076 (poster) 1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)–associated advanced non-squamous non-small cell lung cancer (NS-NSCLC). View abstract Abstract 9077 (poster) A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer). View abstract Abstract 8568 (poster) Pathological central review of 290 thymic epithelial tumors (TET): The national network RYTHMIC experience. View abstract ----------------------------------------------------------------------------------------------------------------CANCERS GYNECOLOGIQUES ARCAGY - Association de Recherche sur les CAncers dont GYnécologiques GINECO - Groupe d’Investigateurs Nationaux pour l’Étude des Cancers Ovariens et du sein Abstract TPS5607 (poster) PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. View abstract Abstract TPS5603 (poster) NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. View abstract Abstract 5575 (poster) Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC). View abstract 3 Lettre d’information des GCO - n°1 – Mai 2016 GCO/IFCT 10 rue de la Grange-Batelière - 75009 Paris Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/ ----------------------------------------------------------------------------------------------------------------CANCERS PEDIATRIQUES SFCE : Société Française de lutte contre les Cancers et les leucémies de l’Enfant et de l’adolescent Abstract 10507 (communication orale) Results of the randomized intergroup trial Inter-B-NHL ritux 2010 for children and adolescents with high risk B-cell non Hodgkin’s lymphoma and mature acute leukemia: Evaluation of rituximab efficacy in addition to standard LMB chemotherapy regimen. View abstract Abstract 10514 (communication orale) Two-year results of clinical efficacy of cisplatin in combination with sodium thiosulfate (STS) vs cisplatin alone in a randomized phase III trial for standard risk hepatoblastoma (SR-HB): SIOPEL 6. View abstract Abstract 10555 (poster) Dose-finding study of vinblastine in combination with nilotinib in children, adolescents and young adults with refractory or recurrent low-grade glioma: Results of the ITCC/SIOPE-Brain VINILO phase I trial (NCT01887522). View abstract Discussing abstracts 10515, 10516, 10517 (communication) Advancing the Care of Children With Rare Malignancies Through Collaboration View abstract ---------------------------------------------------------------------------------------------------------------HEMOPATHIES MALIGNES LYSA : The LYmphoma Study Association Abstract 7509 (communication orale) Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial. View abstract Abstract 7518 (poster) Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study Association (LYSA) trials, the Simonal Study. View abstract Abstract 7547 (poster) Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system. View abstract 4 Lettre d’information des GCO - n°1 – Mai 2016 GCO/IFCT 10 rue de la Grange-Batelière - 75009 Paris Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/ IFM : Intergroupe Francophone du Myélome Abstract 8001 (communication orale) Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). View abstract ---------------------------------------------------------------------------------------------------------------CANCERS DU CERVEAU ET DU SYSTEME NERVEUX CENTRAL IGCNO : InterGroupe Coopérateur de Neuro-Oncologie ANOCEF : Association des Neuro-oncologues d'Expression Française Abstract LBA2 (communication orale) A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). View Abstract Abstract LBA2000 (communication orale) Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. Abstract Abstract 2020 (poster) Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio. Abstract Abstract 2021 (poster) Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo. Abstract Abstract 2033 (poster) Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma. Abstract Abstract 2048 (poster) Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plusradiotherapy plustemozolomide for patients with newly diagnosed glioblastoma (AVAglio). Abstract 5 Lettre d’information des GCO - n°1 – Mai 2016 GCO/IFCT 10 rue de la Grange-Batelière - 75009 Paris Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/ Abstract TPS2083 (poster) MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway. Abstract Abstract e14123 (poster) Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extraterminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB). Abstract Abstract 2015 (poster) Validation of the new glioma WHO classification in the French POLA Network: analysis of 1041 cases. Abstract ----------------------------------------------------------------------------------------------------------------- Plus d’informations sur les GCO : http://www.gco-cancer.org/fr/ Retrouvez tous les abstracts sur le site de l’ASCO : https://iplanner.asco.org/am2016/#/ 6 Lettre d’information des GCO - n°1 – Mai 2016 GCO/IFCT 10 rue de la Grange-Batelière - 75009 Paris Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/